Antion Biosciences takes allogeneic approach to therapies with microRNA technology


October 21, 2022 -- Dr. Sven Kili, CEO of Antion Biosciences, contends that the company’s proprietary technologies take multiplex cell engineering beyond the current capabilities of gene editing, enabling off-the-shelf, efficient, and scalable cellular immunotherapies.

Science Advisory Board spoke with Kili at last week's 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA, where he laid out his vision for where Antion Biosciences is heading and what the industry needs to do to cure diseases with significant unmet medical needs.

"If we want to bring cell and gene therapy into the future, we really need to think about ways of addressing larger patient populations and doing it in a way that is much more efficient," said Kili, who is also co-chair of the International Society for Cell & Gene Therapy annual meeting. "That's really where Antion is moving towards."

Kili said Antion has taken "a look at the technology that's out there at the moment" -- particularly in terms of autologous versus allogeneic -- and the Swiss cell and gene engineering company's microRNA technology (miCAR platform) is a novel way of approaching allogeneic cell creation by enabling simultaneous silencing of multiple gene targets, while overcoming the challenges faced by existing gene editing approaches.

"We can then address many more patients from a lot of cells," Kili said. "That in itself brings down the cost of goods and hopefully makes these therapies much more available to patients."

Watch this video to learn more.


Gene editing advances continue a pace, but progress is still early: panel
With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa say they are...
Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview...
ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic...

Copyright © 2022 scienceboard.net


Conferences
Glasgow International Health Festival
January 25-26, 2023
Glasgow
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter